journal cover

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

The Lancet Oncology

Jul 22, 2017

G V LongMatteo S Carlino

Abstract

Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combinati...read more

Mentioned in this Paper

Monoclonal Antibodies
Antineoplastic Agents
Intravenous
Follow-up
Combination Drug Therapy
Thyroid Dysfunction
Open Label Study
Neoplasms
Tumor Lysis Syndrome
ipilimumab
8
2
1
123
Paper Details
References
  • References
  • Citations20
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations20
12

Similar Papers Found In These Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Graves Disease

Graves disease is common form of hyperthyroidism with a diffuse hyperplastic goiter. It is an autoimmune disorder that produces antibodies against thyroid stimulating hormone receptor. These autoantibodies activate the TSH receptor, thereby stimulating the thyroid gland and hypersecretion of thyroid hormones.Discover the latest research on Graves disease here.

Skin Cutaneous Melanoma

Cutaneous melanoma is a cancer of the pigment-producing cells known as melanocytes. While it has a 98 percent five-year survival rate when caught early, thousands of deaths are attributed to this cancer each year. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Therapy for Autoimmunity

Currently treatments for autoimmune diseases are anti-inflammatory and immunosuppressive, although recent advances in regulatory T cell therapy have shown promise as a potential therapeutic strategy. Discover the latest research on Therapies for Autoimmunity here.

Immuno-Oncology

Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

© 2020 Meta ULC. All rights reserved

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

The Lancet Oncology

Jul 22, 2017

G V LongMatteo S Carlino

PMID: 28729151

DOI: 10.1016/s1470-2045(17)30428-x

Abstract

Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combinati...read more

Mentioned in this Paper

Monoclonal Antibodies
Antineoplastic Agents
Intravenous
Follow-up
Combination Drug Therapy
Thyroid Dysfunction
Open Label Study
Neoplasms
Tumor Lysis Syndrome
ipilimumab
8
2
1
123

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations20
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations20
12
/papers/standard-dose-pembrolizumab-in-combination-with/28729151